Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,9.4,4617,DB08914,"Insulin, isophane"
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,15.4,4618,DB08914,"Insulin, isophane"
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,11.8,4619,DB08914,"Insulin, isophane"
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,9.4,4620,DB08914,"Insulin, isophane"
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,15.4,4621,DB08914,"Insulin, isophane"
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,11.8,4622,DB08914,"Insulin, isophane"
<,8846686,B(o),"In 36 patients, B(o) was < 1.5%, and in 38 patients B(o) was > 10.0%.",The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),%,1.5,7225,DB08914,"Insulin, isophane"
>,8846686,B(o),"In 36 patients, B(o) was < 1.5%, and in 38 patients B(o) was > 10.0%.",The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),%,10.0,7226,DB08914,"Insulin, isophane"
<,8846686,B(o),"Of these, 6 patients, group 1 (B(o) < 1.5%) and 8 patients, group 2 (B(o) > 10.0%), respectively, subsequently participated in a pharmacokinetic study.",The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),%,1.5,7227,DB08914,"Insulin, isophane"
>,8846686,B(o),"Of these, 6 patients, group 1 (B(o) < 1.5%) and 8 patients, group 2 (B(o) > 10.0%), respectively, subsequently participated in a pharmacokinetic study.",The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),%,10.0,7228,DB08914,"Insulin, isophane"
,8846686,areas under the curve (AUC),The areas under the curve (AUC) of free insulin concentration were smaller for group 2 (p = 0.01) than for group 1 (212.2 +/- 22.0 vs 316.8 +/- 25.3 mU l-1h).,The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),[mu] / [l],212.2,7229,DB08914,"Insulin, isophane"
,8846686,areas under the curve (AUC),The areas under the curve (AUC) of free insulin concentration were smaller for group 2 (p = 0.01) than for group 1 (212.2 +/- 22.0 vs 316.8 +/- 25.3 mU l-1h).,The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),[mu] / [l],316.8,7230,DB08914,"Insulin, isophane"
,8846686,AUCs,The AUCs of the glucose infusion rate were also smaller for group 2 (p < 0.05) than for group 1 (2.50 +/- 0.32 vs 3.58 +/- 0.36 g kg-1).,The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),[g] / [kg],2.50,7231,DB08914,"Insulin, isophane"
,8846686,AUCs,The AUCs of the glucose infusion rate were also smaller for group 2 (p < 0.05) than for group 1 (2.50 +/- 0.32 vs 3.58 +/- 0.36 g kg-1).,The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846686/),[g] / [kg],3.58,7232,DB08914,"Insulin, isophane"
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,5.7,9742,DB08914,"Insulin, isophane"
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,12.1,9743,DB08914,"Insulin, isophane"
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,19.9,9744,DB08914,"Insulin, isophane"
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,22.7,9745,DB08914,"Insulin, isophane"
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,23.2,9746,DB08914,"Insulin, isophane"
,15855574,duration of action,"Interpolation of the dose-response relationships for AUC(GIR) (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,16.9,9747,DB08914,"Insulin, isophane"
,15855574,duration of action,"Interpolation of the dose-response relationships for AUC(GIR) (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,12.7,9748,DB08914,"Insulin, isophane"
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[units] / [kg],0.2,9749,DB08914,"Insulin, isophane"
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[units] / [kg],0.4,9750,DB08914,"Insulin, isophane"
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),i,0.3,9751,DB08914,"Insulin, isophane"
,15855574,area over the EGP curve,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[mg] / [kg],636,9752,DB08914,"Insulin, isophane"
,15855574,area over the EGP curve,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[mg] / [kg],584,9753,DB08914,"Insulin, isophane"
,15855574,AUC(P,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,173,9754,DB08914,"Insulin, isophane"
,15855574,AUC(P,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,328,9755,DB08914,"Insulin, isophane"
,7060331,half-life,"Using a biotelemetric technique with small Geiger-Müller detectors applied to the skin surface, the disappearance of 125I-NPH insulin fron subcutis was monoexponential with a mean half-life of 6.6 +/- 3.3 (SD) hr.",Kinetics of subcutaneous NPH insulin in diabetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060331/),h,6.6,48966,DB08914,"Insulin, isophane"
,10826516,areas under the insulin curve,During the observation period of 24 hours the areas under the insulin curve for NPH[0.3 IU/kg] vs. NPH[0.6 IU/kg] were 60 vs.,Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10826516/),,60,81854,DB08914,"Insulin, isophane"
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],14.0,84326,DB08914,"Insulin, isophane"
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],16.5,84327,DB08914,"Insulin, isophane"
,12077738,time to maximal serum glucose concentration (t(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),min,20,84328,DB08914,"Insulin, isophane"
,22758791,onset of action,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,3.5,98187,DB08914,"Insulin, isophane"
,22758791,time to glucose nadir,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,14,98188,DB08914,"Insulin, isophane"
>,22758791,duration of action,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,24,98189,DB08914,"Insulin, isophane"
,2146067,area under the insulin concentration curve,"Thereafter insulin concentrations remained significantly higher for the remaining 360 min of study, reflected by a significantly greater area under the insulin concentration curve for the 420 min study (IM 8630 +/- 1256 vs SC 4908 +/- 465 mU l-1 min, p less than 0.05).",Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146067/),[min·mu] / [l],8630,148571,DB08914,"Insulin, isophane"
,2146067,area under the insulin concentration curve,"Thereafter insulin concentrations remained significantly higher for the remaining 360 min of study, reflected by a significantly greater area under the insulin concentration curve for the 420 min study (IM 8630 +/- 1256 vs SC 4908 +/- 465 mU l-1 min, p less than 0.05).",Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146067/),[min·mu] / [l],4908,148572,DB08914,"Insulin, isophane"
,18793592,maximum GIR,"The maximum GIR were 10.20 mg/kg/min and 9.72 mg/kg/min for Jusline Regular and Humulin Regular, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],10.20,160730,DB08914,"Insulin, isophane"
,18793592,maximum GIR,"The maximum GIR were 10.20 mg/kg/min and 9.72 mg/kg/min for Jusline Regular and Humulin Regular, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],9.72,160731,DB08914,"Insulin, isophane"
,18793592,maximum GIR,"The maximum GIR were 7.09 mg/kg/min and 7.91 mg/kg/min for Jusline NPH and Humulin NPH, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],7.09,160732,DB08914,"Insulin, isophane"
,18793592,maximum GIR,"The maximum GIR were 7.09 mg/kg/min and 7.91 mg/kg/min for Jusline NPH and Humulin NPH, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],7.91,160733,DB08914,"Insulin, isophane"
,18793592,maximum GIR,"The maximum GIR and tGIRmax were 6.39 mg/kg/min and 6.63 mg/kg/ min for Jusline Premixed Regular/NPH (30/70) and Humulin Premixed Regular/NPH (30/70), respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],6.39,160734,DB08914,"Insulin, isophane"
,18793592,tGIRmax,"The maximum GIR and tGIRmax were 6.39 mg/kg/min and 6.63 mg/kg/ min for Jusline Premixed Regular/NPH (30/70) and Humulin Premixed Regular/NPH (30/70), respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [·kg·min],6.63,160735,DB08914,"Insulin, isophane"
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],2.6,182897,DB08914,"Insulin, isophane"
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],2.2,182898,DB08914,"Insulin, isophane"
,9839100,Peak plasma insulin levels,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[ng] / [ml],1.9,182899,DB08914,"Insulin, isophane"
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],121.5,182900,DB08914,"Insulin, isophane"
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],135.0,182901,DB08914,"Insulin, isophane"
,9839100,total glucose infused,"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],117.3,182902,DB08914,"Insulin, isophane"
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],8.3,182903,DB08914,"Insulin, isophane"
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],8.0,182904,DB08914,"Insulin, isophane"
,9839100,maximum glucose infusion rate (GIRmax),"Peak plasma insulin levels (2.6 +/- 0.8 vs. 2.2 +/- 0.6 vs. 1.9 +/- 0.6 ng/ml, P = 0.075), total glucose infused (121.5 +/- 32.8 vs. 135.0 +/- 49.0 vs. 117.3 +/- 39.9 mg.kg-1.min-1, P = 0.53), and maximum glucose infusion rate (GIRmax) (8.3 +/- 0.9 vs. 8.0 +/- 1.7 vs. 7.1 +/- 2.4 mg.kg-1.min-1, P = 0.65) were not significantly different between treatments.",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),[mg] / [kg·min],7.1,182905,DB08914,"Insulin, isophane"
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,0.9,182906,DB08914,"Insulin, isophane"
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,1.2,182907,DB08914,"Insulin, isophane"
,9839100,times until peak insulin concentrations,"The times until peak insulin concentrations were similar in treatment groups A and B, but significantly shorter than in treatment group C (0.9 +/- 0.3 and 1.2 +/- 0.2 vs. 2.0 +/- 0.4 h, respectively, P = 0.042).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),h,2.0,182908,DB08914,"Insulin, isophane"
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,113.9,182909,DB08914,"Insulin, isophane"
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,122.0,182910,DB08914,"Insulin, isophane"
,9839100,times until GIRmax,"The times until GIRmax were also not different (113.9 +/- 41 and 122.0 +/- 45 vs. 209.0 +/- 51.3 min, respectively, P = 0.002).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),min,209.0,182911,DB08914,"Insulin, isophane"
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,239.9,182912,DB08914,"Insulin, isophane"
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,292.4,182913,DB08914,"Insulin, isophane"
,9839100,glucose infusion rate (GIR),"The glucose infusion rate (GIR) then fell to 50% GIRmax more quickly in treatment groups A and B than in treatment group C (239.9 +/- 40.5 vs. 292.4 +/- 133.3 vs. 399.5 +/- 78.3, respectively, P = 0.005).",The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839100/),,399.5,182914,DB08914,"Insulin, isophane"
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,538",187655,DB08914,"Insulin, isophane"
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,081",187656,DB08914,"Insulin, isophane"
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,170",187657,DB08914,"Insulin, isophane"
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.8,189294,DB08914,"Insulin, isophane"
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.5,189295,DB08914,"Insulin, isophane"
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1,189296,DB08914,"Insulin, isophane"
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1.5,189297,DB08914,"Insulin, isophane"
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194793,DB08914,"Insulin, isophane"
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194794,DB08914,"Insulin, isophane"
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194795,DB08914,"Insulin, isophane"
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194796,DB08914,"Insulin, isophane"
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194797,DB08914,"Insulin, isophane"
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194798,DB08914,"Insulin, isophane"
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,21.9,194799,DB08914,"Insulin, isophane"
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,43.8,194800,DB08914,"Insulin, isophane"
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,52.2,194801,DB08914,"Insulin, isophane"
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.9,194802,DB08914,"Insulin, isophane"
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,15.3,194803,DB08914,"Insulin, isophane"
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,13.2,194804,DB08914,"Insulin, isophane"
,1773708,area under the,"Analysis of area under the incremental insulin absorption curve demonstrated that Mixtard produced significantly increased levels compared to syringe-mixed regular: NPH (7.6 +/- 0.8), Actraphane (9.6 +/- 1.0) and Humulin M3 (9.0 +/- 0.8 mU/l all P less than 0.05).",A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773708/),[mu] / [l],7.6,215245,DB08914,"Insulin, isophane"
,1773708,area under the,"Analysis of area under the incremental insulin absorption curve demonstrated that Mixtard produced significantly increased levels compared to syringe-mixed regular: NPH (7.6 +/- 0.8), Actraphane (9.6 +/- 1.0) and Humulin M3 (9.0 +/- 0.8 mU/l all P less than 0.05).",A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773708/),[mu] / [l],9.6,215246,DB08914,"Insulin, isophane"
,1773708,area under the,"Analysis of area under the incremental insulin absorption curve demonstrated that Mixtard produced significantly increased levels compared to syringe-mixed regular: NPH (7.6 +/- 0.8), Actraphane (9.6 +/- 1.0) and Humulin M3 (9.0 +/- 0.8 mU/l all P less than 0.05).",A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773708/),[mu] / [l],9.0,215247,DB08914,"Insulin, isophane"
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,250,265811,DB08914,"Insulin, isophane"
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,170,265812,DB08914,"Insulin, isophane"
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,236,265813,DB08914,"Insulin, isophane"
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,243,265814,DB08914,"Insulin, isophane"
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,38,265815,DB08914,"Insulin, isophane"
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,41,265816,DB08914,"Insulin, isophane"
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,65,265817,DB08914,"Insulin, isophane"
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,35,265818,DB08914,"Insulin, isophane"
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.66,265819,DB08914,"Insulin, isophane"
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.61,265820,DB08914,"Insulin, isophane"
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.80,265821,DB08914,"Insulin, isophane"
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],2.06,265822,DB08914,"Insulin, isophane"
